Das MEDICA LABMED FORUM findet vom 16. bis 19. November 2026 auf der MEDICA in Düsseldorf statt. Ideele Partner sind die DGKL und der VDGH.
<a href="https://medlabportal.de/medica-labmed-forum-expertentreff-fuer-labormedizin-in-halle-1/" class="hover:underline text-blue-600 dark:text-sky-400 no-card-link" target="_blank" rel="noopener" data-link="bsky">https://medlabportal.de/medica-labmed-forum-expertentreff-fuer-labormedizin-in-halle-1/
Das MEDICA LABMED FORUM findet vom 16. bis 19. November 2026 auf der MEDICA in Düsseldorf statt. Ideele Partner sind die DGKL und der VDGH.
<a href="https://medlabportal.de/medica-labmed-forum-expertentreff-fuer-labormedizin-in-halle-1/" class="hover:underline text-blue-600 dark:text-sky-400 no-card-link" target="_blank" rel="noopener" data-link="bsky">https://medlabportal.de/medica-labmed-forum-expertentreff-fuer-labormedizin-in-halle-1/
On this special occasion, #LabMedDiscovery extends our warmest wishes to our authors, reviewers, Editorial Board members, readers, and partners in China and around the world.
United by science, connected through discovery.
🌏 Together, we advance labmed
On this special occasion, #LabMedDiscovery extends our warmest wishes to our authors, reviewers, Editorial Board members, readers, and partners in China and around the world.
United by science, connected through discovery.
🌏 Together, we advance labmed
www.sciencedirect.com/science/arti...
www.sciencedirect.com/science/arti...
New in LabMed Discovery: Lippi and colleagues explore:
🔬 Validation & continuous monitoring
⚖️ Ethics & governance
👩⚕️ Human oversight
🔗 doi.org/10.1016/j.lm...
#AI #LaboratoryMedicine #PatientSafety
New in LabMed Discovery: Lippi and colleagues explore:
🔬 Validation & continuous monitoring
⚖️ Ethics & governance
👩⚕️ Human oversight
🔗 doi.org/10.1016/j.lm...
#AI #LaboratoryMedicine #PatientSafety
Ruijin Hospital’s journal portfolio, including LabMed Discovery, was showcased at the Shanghai journal conference.
🌏 Connecting research, clinical practice and global readers.
#LMD #RuijinHospital #SciComm
Ruijin Hospital’s journal portfolio, including LabMed Discovery, was showcased at the Shanghai journal conference.
🌏 Connecting research, clinical practice and global readers.
#LMD #RuijinHospital #SciComm
LMD’s editorial team was honored to deliver remarks at CSCO’s clinical case reasoning competition.
🌏 Sharing diagnostic insights with a global audience through LabMed Discovery.
#LMD #CSCO #LaboratoryMedicine
LMD’s editorial team was honored to deliver remarks at CSCO’s clinical case reasoning competition.
🌏 Sharing diagnostic insights with a global audience through LabMed Discovery.
#LMD #CSCO #LaboratoryMedicine
🌏 LabMed Discovery’s 2nd Editorial Board Meeting | Shanghai, Sept 15
🤝 Welcoming new board members and shaping LMD’s next chapter together.
🔬 Connecting minds. Advancing laboratory medicine.
#LMD #LaboratoryMedicine
🌏 LabMed Discovery’s 2nd Editorial Board Meeting | Shanghai, Sept 15
🤝 Welcoming new board members and shaping LMD’s next chapter together.
🔬 Connecting minds. Advancing laboratory medicine.
#LMD #LaboratoryMedicine
📚 LabMed Discovery was invited to deliver a talk at a conference on science, technology and journals.
🤝 Sharing perspectives and building connections to advance scholarly publishing.
#LMD #ScholarlyPublishing
📚 LabMed Discovery was invited to deliver a talk at a conference on science, technology and journals.
🤝 Sharing perspectives and building connections to advance scholarly publishing.
#LMD #ScholarlyPublishing
New in LabMed Discovery: a review proposes precision care for gastric & colorectal cancers through:
🧬 Multi-omics
🩸 Serial ctDNA monitoring
🤖 AI integration
🔗 doi.org/10.1016/j.lm...
#PrecisionOncology #LiquidBiopsy
New in LabMed Discovery: a review proposes precision care for gastric & colorectal cancers through:
🧬 Multi-omics
🩸 Serial ctDNA monitoring
🤖 AI integration
🔗 doi.org/10.1016/j.lm...
#PrecisionOncology #LiquidBiopsy
📍 Wuhan, Sept 17–19
LabMed Discovery was honored to join the 20th National Congress of Laboratory Medicine.
🤝 Connecting with colleagues and bringing laboratory medicine research to a global audience!
#LMD #NCLM2026 #LaboratoryMedicine
📍 Wuhan, Sept 17–19
LabMed Discovery was honored to join the 20th National Congress of Laboratory Medicine.
🤝 Connecting with colleagues and bringing laboratory medicine research to a global audience!
#LMD #NCLM2026 #LaboratoryMedicine
🔬 A new review in LabMed Discovery examines the measurement gap.
🎯 Key insights: assay limitations, reliable quantification & a roadmap to clinical validation.
🔗 doi.org/10.1016/j.lm...
#RNA #CancerBiomarkers
🔬 A new review in LabMed Discovery examines the measurement gap.
🎯 Key insights: assay limitations, reliable quantification & a roadmap to clinical validation.
🔗 doi.org/10.1016/j.lm...
#RNA #CancerBiomarkers
🧬 Can human genetics unlock new clues to thyroid disease?
🌿 PITO links genetic evidence, molecular networks & traditional Chinese medicine to prioritize potential targets for hyper- and hypothyroidism.
🔎 Explore the latest in LMD!
#Thyroid sciencedirect.com/science/arti...
🧬 Can human genetics unlock new clues to thyroid disease?
🌿 PITO links genetic evidence, molecular networks & traditional Chinese medicine to prioritize potential targets for hyper- and hypothyroidism.
🔎 Explore the latest in LMD!
#Thyroid sciencedirect.com/science/arti...
#DEI #labmed #pathology
tinyurl.com/LeadinDEI
#DEI #labmed #pathology
tinyurl.com/LeadinDEI
How can laboratory innovation transform clinical decision-making and advance precision medicine?
🔗 Submit your manuscript:
www.editorialmanager.com/lmd/Default....
How can laboratory innovation transform clinical decision-making and advance precision medicine?
🔗 Submit your manuscript:
www.editorialmanager.com/lmd/Default....
In LabMed Discovery, Rengarajan maps 5 leading platforms—subunit, viral vector, VLP, mRNA and DNA—and the safety, clinical-trial and scalability gaps still ahead.
Read: doi.org/10.1016/j.lm...
#NipahVirus #Vaccines
In LabMed Discovery, Rengarajan maps 5 leading platforms—subunit, viral vector, VLP, mRNA and DNA—and the safety, clinical-trial and scalability gaps still ahead.
Read: doi.org/10.1016/j.lm...
#NipahVirus #Vaccines
A Phase III trial in LabMed Discovery found that C-TST achieved 83.0% sensitivity, 100% specificity and no serious adverse events.
Read open access:
doi.org/10.1016/j.lm...
#Tuberculosis #Pediatrics #LabMedicine
A Phase III trial in LabMed Discovery found that C-TST achieved 83.0% sensitivity, 100% specificity and no serious adverse events.
Read open access:
doi.org/10.1016/j.lm...
#Tuberculosis #Pediatrics #LabMedicine
🌍 Open Access — Your research is freely accessible worldwide
💰 No APC for authors — covered by Ruijin Hospital, Shanghai Jiao Tong University School of Medicine
⚡ Fast & rigorous peer review — Ensuring quality and efficiency
🌍 Open Access — Your research is freely accessible worldwide
💰 No APC for authors — covered by Ruijin Hospital, Shanghai Jiao Tong University School of Medicine
⚡ Fast & rigorous peer review — Ensuring quality and efficiency